Close
CDMO Safety Testing 2026
Novotech

News

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially finalized a comprehensive licensing agreement. Under the terms of the worldwide arrangement, Sonefpeglutide licensing is for global development, manufacturing, and commercialization, excluding the South Korean market. The financial framework includes...

Pharmacogenomics in 2026: From Research Concept to Clinical Workflow

Pharmacogenomics has moved well beyond the research phase. In 2026, healthcare systems are using genetic insights as part of routine prescribing decisions, especially in areas such as oncology, cardiology, psychiatry, and pain management. What once sat inside academic journals...

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

The Pfizer Innovent Cancer Deal has been finalized, establishing a global licensing and collaboration agreement valued at up to $10.5 billion. The transaction focuses on the research, development, and commercialization of 12 early-stage oncology programs. This arrangement combines the...

The Push for Greater Accuracy in Clinical Trials

Clinical trials are the foundation of modern medicine. Every treatment, therapy, and medical breakthrough relies on accurate research to ensure safety and effectiveness. However, maintaining accuracy across complex studies has always been a challenge. With large patient populations, multiple...

The Four Principles of Medicines Optimisation in Primary Care

Medicines optimisation in primary care became a formal discipline in 2013, when the Royal Pharmaceutical Society set out a four-principle framework that has guided the work ever since. The language was new at the time, but the underlying ideas...

MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours

MSD and Adcendo have established a collaboration and supply agreement to evaluate the combination of ADCE-T02 and pembrolizumab. The companies are preparing for a Phase Ib solid tumour clinical trial targeting patients with advanced solid tumours. Adcendo will act as...

SK Bioscience Inks Colombia Vaccine Localization Deal

In a critical step for Colombia vaccine localization, SK Bioscience will execute a vaccine technology transfer with Colombiaโ€™s state-owned pharmaceutical enterprise, VECOL. The partnership focuses on building a local manufacturing site to align with the country's national vaccine localization...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป